XBIO

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Xenetic Biosciences Inc

NASDAQ | XBIO

2.58

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 26, 2025)

$5.91M

Market Cap

-

P/E Ratio

-2.1

EPS

$13.93

52 Week High

$2.20

52 Week Low

HEALTHCARE

Sector

XBIO Chart

Recent Chart
Price Action

XBIO Technicals

Tags:

XBIO Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $2.5M
Total Revenue $2.5M
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$4.2M
Selling General And Administrative $3.4M
Research And Development $3.3M
Operating Expenses $6.7M
Investment Income Net -
Net Interest Income $250K
Interest Income $250K
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $153K
Income Before Tax -$4M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$4M
Comprehensive Income Net Of Tax -
Ebit -$4.2M
Ebitda -$4.1M
Net Income -$4M

Revenue & Profitability

Earnings Performance

XBIO Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $6.9M
Total Current Assets $6.6M
Cash And Cash Equivalents At Carrying Value $6.2M
Cash And Short Term Investments $6.2M
Inventory -
Current Net Receivables -
Total Non Current Assets $314K
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $422K
Other Non Current Assets -
Total Liabilities $894K
Total Current Liabilities $894K
Current Accounts Payable $284K
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $0
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total -
Other Current Liabilities $611K
Other Non Current Liabilities -
Total Shareholder Equity $6M
Treasury Stock -
Retained Earnings -$197M
Common Stock $1.5K
Common Stock Shares Outstanding $1.5M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$2.8M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization -
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -
Cashflow From Financing -
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$4M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $2.5M
Total Revenue $2.5M
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$4.2M
Selling General And Administrative $3.4M
Research And Development $3.3M
Operating Expenses $6.7M
Investment Income Net -
Net Interest Income $250K
Interest Income $250K
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $153K
Income Before Tax -$4M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$4M
Comprehensive Income Net Of Tax -
Ebit -$4.2M
Ebitda -$4.1M
Net Income -$4M

XBIO News

XBIO Profile

Xenetic Biosciences Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Xenetic Biosciences Inc. is an innovative biopharmaceutical company based in Framingham, Massachusetts, focused on advancing next-generation therapies for cancer. Utilizing its proprietary XCART platform, the company is at the forefront of developing personalized chimeric antigen receptor T (CAR T) cell therapies that target unique tumor neoantigens, allowing for tailored treatment options for individual patients. With a strong commitment to addressing significant unmet medical needs in oncology, Xenetic aims to improve treatment efficacy and solidify its position as a leader in the rapidly evolving field of personalized medicine.

LPTX
+368.57%
$2.05
NVDA
+1.37%
$180.26
VHAI
0.00%
$0.00
BYND
+19.00%
$1.02
KTTA
+117.39%
$1.06
INHD
-16.32%
$0.22
ZYXI
+115.62%
$1.59
VINE
+10.76%
$0.39
AMZE
+10.76%
$0.39
ONDS
-2.36%
$8.24
AMBR
+56.32%
$2.47
BITF
+11.91%
$3.10
PLUG
+1.53%
$1.98
NIO
-0.72%
$5.46
IPG
-1.95%
$24.57
ASST
+1.80%
$1.13
CLSK
+13.79%
$13.45
AXDX
-61.36%
$0.03
AAL
+3.49%
$13.93
TSLA
+1.71%
$426.58
CIFR
+9.30%
$19.15
SOFI
+0.56%
$28.49
INTC
+2.73%
$36.81
BMNR
+9.78%
$31.74
GPUS
+15.78%
$0.33
GOOGL
-1.07%
$319.95
SPRC
-9.01%
$2.22
ADAP
-15.14%
$0.05
YGMZ
-34.15%
$0.12
MARA
-0.53%
$11.11
WULF
+6.45%
$14.84
HOOD
+10.92%
$128.20
RUBI
-8.19%
$0.21
KVUE
+1.11%
$17.22
F
+0.15%
$13.19
AMD
+3.93%
$214.24
SNDK
-2.47%
$215.04
SOND
-23.45%
$0.12
WBD
+4.00%
$23.88
DNN
+3.64%
$2.56
RMBL
+60.50%
$3.21
TLRY
+4.76%
$1.03
BTBT
+2.65%
$2.32
LNW
-3.71%
$86.22
CHR
-4.86%
$0.04
AMZN
-0.22%
$229.16
ADD
-25.47%
$0.05
GRAB
+1.52%
$5.32
BMNU
+18.42%
$7.52
RIG
+6.17%
$4.30
RIVN
+3.98%
$16.18
PW
+18.87%
$0.99
SRM
+53.27%
$10.30
PLTR
+1.35%
$165.77
PFE
-0.03%
$25.71
AAPL
+0.20%
$277.55
HBAN
+0.55%
$16.27
IVP
-20.80%
$0.13
BBD
+3.95%
$3.68
AGNC
+1.53%
$10.56
CETY
-11.20%
$2.06
BTG
+3.23%
$4.47
BAC
+0.97%
$52.99
KALA
+42.62%
$0.91
CCL
-1.12%
$25.43
BULL
+6.43%
$9.26
SNAP
-0.39%
$7.61
GOOG
-1.03%
$320.28
TWOH
0.00%
$0.00
ACHR
+1.49%
$7.49
RGTI
-1.95%
$25.57
CRWV
+4.20%
$74.29
AVGO
+3.25%
$397.57
WLGS
-5.57%
$0.04
VALE
+2.62%
$12.51
ABEV
0.00%
$2.51
NFLX
+1.66%
$106.14
MTSR
-0.35%
$70.50
PLTD
-1.37%
$7.16
T
-0.15%
$25.82
AEHL
+8.43%
$3.47
IREN
+2.06%
$48.45
ORCL
+4.02%
$204.96
UPWK
-0.55%
$19.58
NTNX
-17.74%
$48.34
MSFT
+1.78%
$485.50
ITUB
+3.23%
$7.66
DVLT
-3.61%
$2.13
PCG
+1.78%
$16.01
NOK
+0.33%
$6.08
DEFT
+20.86%
$1.39
CMG
+1.88%
$34.03
AFMD
-34.94%
$0.18
KOS
-1.83%
$1.07
HBI
-0.45%
$6.59
CAN
+0.75%
$0.92
HPQ
-1.39%
$23.98
BURU
+7.72%
$0.22
PLTZ
-2.62%
$7.43
APLD
+5.05%
$24.94
LPTX
+368.57%
$2.05
NVDA
+1.37%
$180.26
VHAI
0.00%
$0.00
BYND
+19.00%
$1.02
KTTA
+117.39%
$1.06
INHD
-16.32%
$0.22
ZYXI
+115.62%
$1.59
VINE
+10.76%
$0.39
AMZE
+10.76%
$0.39
ONDS
-2.36%
$8.24
AMBR
+56.32%
$2.47
BITF
+11.91%
$3.10
PLUG
+1.53%
$1.98
NIO
-0.72%
$5.46
IPG
-1.95%
$24.57
ASST
+1.80%
$1.13
CLSK
+13.79%
$13.45
AXDX
-61.36%
$0.03
AAL
+3.49%
$13.93
TSLA
+1.71%
$426.58
CIFR
+9.30%
$19.15
SOFI
+0.56%
$28.49
INTC
+2.73%
$36.81
BMNR
+9.78%
$31.74
GPUS
+15.78%
$0.33
GOOGL
-1.07%
$319.95
SPRC
-9.01%
$2.22
ADAP
-15.14%
$0.05
YGMZ
-34.15%
$0.12
MARA
-0.53%
$11.11
WULF
+6.45%
$14.84
HOOD
+10.92%
$128.20
RUBI
-8.19%
$0.21
KVUE
+1.11%
$17.22
F
+0.15%
$13.19
AMD
+3.93%
$214.24
SNDK
-2.47%
$215.04
SOND
-23.45%
$0.12
WBD
+4.00%
$23.88
DNN
+3.64%
$2.56
RMBL
+60.50%
$3.21
TLRY
+4.76%
$1.03
BTBT
+2.65%
$2.32
LNW
-3.71%
$86.22
CHR
-4.86%
$0.04
AMZN
-0.22%
$229.16
ADD
-25.47%
$0.05
GRAB
+1.52%
$5.32
BMNU
+18.42%
$7.52
RIG
+6.17%
$4.30
RIVN
+3.98%
$16.18
PW
+18.87%
$0.99
SRM
+53.27%
$10.30
PLTR
+1.35%
$165.77
PFE
-0.03%
$25.71
AAPL
+0.20%
$277.55
HBAN
+0.55%
$16.27
IVP
-20.80%
$0.13
BBD
+3.95%
$3.68
AGNC
+1.53%
$10.56
CETY
-11.20%
$2.06
BTG
+3.23%
$4.47
BAC
+0.97%
$52.99
KALA
+42.62%
$0.91
CCL
-1.12%
$25.43
BULL
+6.43%
$9.26
SNAP
-0.39%
$7.61
GOOG
-1.03%
$320.28
TWOH
0.00%
$0.00
ACHR
+1.49%
$7.49
RGTI
-1.95%
$25.57
CRWV
+4.20%
$74.29
AVGO
+3.25%
$397.57
WLGS
-5.57%
$0.04
VALE
+2.62%
$12.51
ABEV
0.00%
$2.51
NFLX
+1.66%
$106.14
MTSR
-0.35%
$70.50
PLTD
-1.37%
$7.16
T
-0.15%
$25.82
AEHL
+8.43%
$3.47
IREN
+2.06%
$48.45
ORCL
+4.02%
$204.96
UPWK
-0.55%
$19.58
NTNX
-17.74%
$48.34
MSFT
+1.78%
$485.50
ITUB
+3.23%
$7.66
DVLT
-3.61%
$2.13
PCG
+1.78%
$16.01
NOK
+0.33%
$6.08
DEFT
+20.86%
$1.39
CMG
+1.88%
$34.03
AFMD
-34.94%
$0.18
KOS
-1.83%
$1.07
HBI
-0.45%
$6.59
CAN
+0.75%
$0.92
HPQ
-1.39%
$23.98
BURU
+7.72%
$0.22
PLTZ
-2.62%
$7.43
APLD
+5.05%
$24.94
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.